KalVista Pharmaceuticals, Inc. (KALV)
NASDAQ: KALV · Real-Time Price · USD
17.30
+1.07 (6.59%)
At close: Mar 9, 2026, 4:00 PM EDT
17.35
+0.05 (0.29%)
After-hours: Mar 9, 2026, 4:23 PM EDT
KalVista Pharmaceuticals Employees
KalVista Pharmaceuticals had 270 employees as of April 30, 2025. The number of employees increased by 120 or 80.00% compared to the previous year.
Employees
270
Change (1Y)
120
Growth (1Y)
80.00%
Revenue / Employee
$5,281
Profits / Employee
-$752,211
Market Cap
874.45M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| MannKind | 592 |
| Phathom Pharmaceuticals | 371 |
| Xencor | 250 |
| Omeros | 202 |
| Sana Biotechnology | 194 |
| Kura Oncology | 192 |
| CytomX Therapeutics | 121 |
| Janux Therapeutics | 109 |
KALV News
- 5 days ago - KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
- 7 days ago - KalVista Pharmaceuticals Presents New Data Highlighting High Patient Satisfaction and Evolving Treatment Trends with EKTERLY® (sebetralstat) - Business Wire
- 12 days ago - KalVista Pharmaceuticals to Present at Upcoming Investor Conferences - Business Wire
- 19 days ago - KalVista Pharmaceuticals Announces Inclusion of EKTERLY® (sebetralstat) as a First-Line Therapy for Adolescents 12 and Older in International Pediatric HAE Guideline - Business Wire
- 25 days ago - KalVista Pharmaceuticals to Present EKTERLY® (sebetralstat) Data at the 2026 American Academy of Allergy, Asthma & Immunology Annual Meeting - Business Wire
- 26 days ago - KalVista: Next Stage Of Growth For EKTERLY Lies With Pediatric Label Expansion - Seeking Alpha
- 2 months ago - KalVista Details Early Sales, Prescriber Uptake For Newly Approved Rare Swelling Drug - Benzinga
- 2 months ago - KalVista Pharmaceuticals Provides Update on Strong EKTERLY® Launch with Preliminary Fourth Quarter and Full Year 2025 Revenue Results - Business Wire